Results 201 to 210 of about 8,441,406 (356)

H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus.

, 1975
Peter C. Doherty, R M Zinkernagel
openalex   +1 more source

INDUCTION OF T LYMPHOCYTES FROM PRECURSOR CELLS IN VITRO BY A PRODUCT OF THE THYMUS [PDF]

, 1973
Koshi Komuro, Edward A. Boyse
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Bacterial Vaginosis-Associated Prevotella timonensis Enhances Dendritic Cell-T Cell Clustering and Subsequent T Cell Proliferation. [PDF]

Eur J Immunol
van Smoorenburg MY, Nerwinska JL, van Hamme JL, Remmerswaal EBM, Segui-Perez C, Strijbis K, Geijtenbeek TBH.   +6 more
europepmc   +1 more source

Detection, isolation, and functional characterization of two human T-cell subclasses bearing unique differentiation antigens. [PDF]

, 1977
Robert L. Evans, J Bréard, Herbert Lazarus, Stuart F. Schlossman, Leonard Chess   +4 more
openalex   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Single-Cell Transcriptome Reveals the Heterogeneity of T Cells in Mice with Systemic Lupus Erythematosus and Neuronal Inflammation

Journal of Inflammation Research
Zhijie Shi, Haihong Qin, Hao Wu Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Haihong Qin; Hao Wu, Email tjqhh1982@163.com; seaseewh@163.comIntroduction: Systemic lupus erythematosus is a heterogeneous autoimmune disease.
Shi Z, Qin H, Wu H
doaj  

Specificity and Suppressor Function of Human T Cells Responsive to Autologous Non-T Cells [PDF]

, 1979
Tsuyoshi Sakane, Ira Green
openalex   +1 more source

Cell cycle, cell division, cell death

Molecular Biology of the Cell, 2019
Jan M. Skotheim, Amy Shaub Maddox
openaire   +2 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source